# Efficacy and safety of Yingxin pill for stable angina pectoris with heart blood stasis obstruction syndrome: a randomized, single-blind, positive-controlled trial

## TL;DR

This study found that Yingxin Pill, when added to standard treatment, is as effective and safe as another traditional medicine for treating stable angina with heart blood stasis.

## Contribution

The study provides clinical evidence for the efficacy and safety of Yingxin Pill in treating stable angina with heart blood stasis syndrome.

## Key findings

- Both groups showed significant improvements in symptoms, lipid profiles, and inflammation markers.
- Yingxin Pill and Shexiang Baoxin Pill had similar effectiveness and safety profiles.
- No significant differences were found in outcomes or adverse events between the two groups.

## Abstract

To evaluate the clinical efficacy and safety of Yingxin Pill (YXP) in patients with stable angina pectoris (SAP) and heart blood stasis obstruction syndrome.

Sixty patients were randomly assigned to either the experimental group (YXP plus conventional Western medicine) or the control group (Shexiang Baoxin Pill [SBP] plus conventional Western medicine), with 30 patients in each group. Treatment lasted for 4 weeks. Outcomes included the Seattle Angina Questionnaire (SAQ), a Traditional Chinese Medicine (TCM) efficacy scale, blood lipid profiles, and inflammatory markers. The effective rate and incidence of adverse events were also compared.

After treatment, both groups showed significant improvements in SAQ scores, TCM efficacy scale scores, lipid profiles, and inflammatory markers compared to baseline (P < 0.05). There were no significant differences between the two groups in these outcomes, nor in the total effective rate or incidence of adverse events (P > 0.05).

The addition of YXP to conventional therapy can improve symptoms, reduce blood lipid and inflammation levels, and is safe for patients with SAP and heart blood stasis obstruction syndrome.

https://itmctr.ccebtcm.org.cn/, identifier ITMCTR2025000274.